Semaglutide, a type of GLP-1R agonists with 94% sequence homology to GLP-1 and with an extended half-life of approximately 1 week, has been clinically approved to treat T2DM and is available in subcutaneous and oral dosage form (136, 137)
Lancet (2019) 394(10192):3950
Ozempic is also not approved as a treatment for people who have type 1 diabetes
doi: 10.1007/s00125-022-05787-2 [DOI] [PMC free article] [PubMed] [Google Scholar] 7.American Diabetes Association Professional Practice Committee
High insulin levels can contribute to atherosclerosis (hardening and narrowing of the arteries), high blood pressure, and abnormal lipid profiles (elevated triglycerides and decreased HDL cholesterol), all of which are risk factors for heart disease and stroke
Compounded semaglutide programs start around $133/month at the budget end and average $179-$229/month for established providers